Anti-platelet or anti-coagulant agent for prevention of ischemic stroke in patients with end-stage renal disease and atrial fibrillation, is it necessary?

JIEN-JIUN CHENLIAN-YU LINYang Y.-H.HWANG, JUEY-JENJUEY-JENHWANGPAU-CHUNG CHENJIUNN-LEE LIN2022-02-152022-02-1520150167-5273https://www.scopus.com/inward/record.uri?eid=2-s2.0-84937440171&doi=10.1016%2fj.ijcard.2015.05.162&partnerID=40&md5=904f6322035aebb60d7c3adda3c3a88fhttps://scholars.lib.ntu.edu.tw/handle/123456789/594523[SDGs]SDG3acetylsalicylic acid; anticoagulant agent; antithrombocytic agent; clopidogrel; ticlopidine; warfarin; anticoagulant agent; antithrombocytic agent; anticoagulant therapy; atrial fibrillation; bleeding tendency; brain hemorrhage; brain ischemia; CHADS2 score; drug effect; end stage renal disease; high risk patient; human; Letter; long term care; neuroprotection; priority journal; propensity score; proportional hazards model; atrial fibrillation; brain ischemia; female; Kidney Failure, Chronic; male; Stroke; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Female; Humans; Kidney Failure, Chronic; Male; Platelet Aggregation Inhibitors; StrokeAnti-platelet or anti-coagulant agent for prevention of ischemic stroke in patients with end-stage renal disease and atrial fibrillation, is it necessary?journal article10.1016/j.ijcard.2015.05.162260732132-s2.0-84937440171